Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic …
HM Kantarjian, JE Cortes, S O'Brien, R Luthra, F Giles… - Blood, 2004 - ashpublications.org
We reviewed 261 patients with chronicphase chronic myelogenous leukemia (CML) after
interferon-α (IFN-α) failure treated with imatinib mesylate 400 mg daily. With a median follow …
interferon-α (IFN-α) failure treated with imatinib mesylate 400 mg daily. With a median follow …
Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia
T Hughes, S Branford - Blood reviews, 2006 - Elsevier
Molecular monitoring of BCR–ABL transcript levels by real-time quantitative PCR is
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and …
S Branford, JF Seymour, A Grigg, C Arthur… - Clinical Cancer …, 2007 - AACR
Purpose: In the first years of imatinib treatment, BCR-ABL remained detectable in all but a
small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL …
small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL …
Genomic and proteomic biomarkers for cancer: a multitude of opportunities
MA Tainsky - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2009 - Elsevier
Biomarkers are molecular indicators of a biological status, and as biochemical species can
be assayed to evaluate the presence of cancer and therapeutic interventions. Through a …
be assayed to evaluate the presence of cancer and therapeutic interventions. Through a …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or-intolerant patients with Philadelphia …
S Branford, DW Kim, S Soverini, A Haque… - Journal of clinical …, 2012 - ascopubs.org
Purpose The association between initial molecular response and longer-term outcomes with
nilotinib was examined. Patients and Methods Patients with imatinib-resistant or-intolerant …
nilotinib was examined. Patients and Methods Patients with imatinib-resistant or-intolerant …
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic …
RD Press, C Galderisi, R Yang, C Rempfer… - Clinical Cancer …, 2007 - AACR
Purpose: Imatinib induces a complete cytogenetic response (CCR) in most chronic myeloid
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
F Palandri, F Castagnetti, N Testoni, S Luatti… - …, 2008 - haematologica.org
Background Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In
patients with advanced phase of the disease, the advent of imatinib significantly increased …
patients with advanced phase of the disease, the advent of imatinib significantly increased …
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C
MC Müller, N Gattermann, T Lahaye, MWN Deininger… - Leukemia, 2003 - nature.com
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …